Abstract:Tuberculosis and fungal infections can pose serious threats to human health. In order to find novel antimicrobial agents, 26 novel quinoxaline-1,4-di-N-oxides containing a thiazolidinone moiety were designed and synthesized, and their antimycobacterial activities were evaluated. Among them, compounds2t,2u,2y, and2zdisplayed the most potent antimycobacterial activity againstMycobacterium tuberculosisstrain H37Rv (minimal inhibitory concentration [MIC] = 1.56 mu g/mL). The antifungal activity of all the compounds was also evaluated againstCandida albicans, Candida tropicalis, Aspergillus fumigatus, andCryptococcus neoformans. Compounds2t,2u,2y, and2zexhibited potential antifungal activities, with an MIC between 2 and 4 mu g/mL. Comparative molecular field analysis (CoMFA:q(2)= 0.914,r(2)= 0.967) and comparative molecular similarity index analysis (CoMSIA:q(2)= 0.918,r(2)= 0.968) models were established to investigate the structure and antimycobacterial activity relationship. The results of contour maps revealed that electronegative and sterically bulky substituents play an important role in the antimycobacterial activity. Electronegative and sterically bulky substituents are preferred at the C7 position of the quinoxaline ring and the C4 position of the phenyl group to increase the antimycobacterial activity. Additionally, more hydrogen bond donor substituents should be considered at the C2 side chain of the quinoxaline ring to improve the activity.

Design, Synthesis and Antimycobacterial Activity of Less Lipophilic Q203 Derivatives Containing Alkaline Fused Ring Moieties.

Exploration of isoxazole‐carboxylic acid methyl ester based 2‐substituted quinoline derivatives as promising antitubercular agents

Design, synthesis and antimycobacterial activity of novel nitrobenzamide derivatives

Design, Synthesis, and Biological Evaluation of 1,2,4-Triazole Derivatives As Potent Antitubercular Agents

Design, synthesis and antimycobacterial activity of 3,5-dinitrobenzamide derivatives containing fused ring moieties.

Synthesis and Antitubercular Evaluation of Reduced Lipophilic Imidazo[1,2-A]pyridine-3-carboxamide Derivatives

Synthesis, 3D-QSAR Analysis and Biological Evaluation of Quinoxaline 1,4-Di-n-oxide Derivatives As Antituberculosis Agents

Synthesis, antimycobacterial and antibacterial activity of fluoroquinolone derivatives containing an 3-alkoxyimino-4-(cyclopropylanimo)methylpyrrolidine moiety

Synthesis, In Vitro Antimycobacterial And Antibacterial Evaluation Of Imb-070593 Derivatives Containing A Substituted Benzyloxime Moiety

Design, Synthesis, and Biological Evaluation of Novel Thiazolidinone-Containing Quinoxaline-1,4-di-<i>N</i>-oxides as Antimycobacterial and Antifungal Agents

Design, synthesis and antimycobacterial activity of novel benzothiazinones with improved water solubility

Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides As Novel Antitubercular Agents.

Design, synthesis and antitubercular evaluation of benzothiazinones containing an oximido or amino nitrogen heterocycle moiety

Design, Synthesis, and Antitubercular Activity of 3‐amidophenols with 5‐heteroatomic Substitutions

Design, synthesis and biological activity of N-(amino)piperazine-containing benzothiazinones against Mycobacterium tuberculosis

Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.

Design, Synthesis and Antitubercular Evaluation of New 2-Amino-5-(4-(benzyloxy)benzyl)thiophene-3-carboxylic Acid Derivatives. Part 3

Design, Synthesis, and Evaluation of the Antitubercular Activity of 5-Phenyl Substituted-5, 6-dihydropyrido[2, 3- d ]pyrimidine-4, 7( 3H , 8H )-dione Compounds

Design, synthesis, and biological evaluation of m-amidophenol derivatives as a new class of antitubercular agents.

Synthesis, evaluation and CoMFA/CoMSIA study of nitrofuranyl methyl N-heterocycles as novel antitubercular agents.

3H-1,2,4-dithiazol-3-one Compounds As Novel Potential Affordable Antitubercular Agents.